Project type: Charles University Mini-grant 2023
Flagship: Flagship 1
Project leader at CU: prof. MUDr. Zuzana Moťovská, Ph.D. (Third Faculty of Medicine)
Participating universities: Heidelberg University, Sorbonne University, University of Warsaw, Harvard University (external parnter)
The DAPT SHOCK AMI randomized study aims to provide yet completely missing evidence of optimal antiplatelet therapy in patients with AMI complicated by CS. Antiplatelet therapy is an essential part of pharmacological treatment to restore flow in the infarct-related coronary artery and is crucial for the prognosis of patients affected by this event. The study purpose is to compare the efficacy of intravenous and direct-acting cangrelor versus recommended therapy with orally administered ticagrelor on the incidence of major cardiovascular events in patients with AMI initially. complicated with CS who are undergoing primary percutaneous coronary intervention. The results of this study will significantly contribute to optimizing antiplatelet treatment in patients with CS caused by AMI.